New pill aims to stop High-Risk lymphoma relapse after cell treatment

NCT ID NCT05256641

Recruiting now Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether the drug acalabrutinib, taken as a pill, can safely prevent relapse in people with very high-risk large B-cell lymphoma after they receive cell therapy (stem cell transplant or CAR T-cells). The trial will enroll 24 adults aged 18-70. Researchers will track how many patients stop the drug due to side effects and how long they stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acalabrutinib (a targeted cancer drug taken as a pill)
What this could lead to: If it works, this could help prevent lymphoma from coming back in patients who are at very high risk of relapse after cell therapy.
What could go wrong: This is an early-phase trial with only 24 people, so results may not apply to everyone. Acalabrutinib may cause side effects that lead some patients to stop taking it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma large B-cell lymphoma primary central nervous system lymphoma Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA HIGH-GRADE B-CELL LYMPHOMA SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA TRANSFORMED LYMPHOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States
University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States
University of Oklahoma
NOT_YET_RECRUITING

Oklahoma City, Oklahoma, 73190, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.